Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe page’s displayed release/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a minor site maintenance update rather than a change to the trial information.SummaryDifference0.1%

- Check10 days agoChange Detected- Site software revision updated to version v3.5.2.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check38 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page revision was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 with no changes to the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the Study Details page.SummaryDifference0.1%

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.